ERS Genomics licenses CRISPR gene editing technology to Daiichi Sankyo
Singapore, Jan. 14 -- ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, has announced the signing of a license agreement with Daiichi Sankyo, a global pharmaceutical company with corporate origins in Japan.
The agreement provides Daiichi Sankyo with access to CRISPR/Cas9 genome editing technology intellectual property for use in its internal research and development.
ERS Genomics holds an exclusive worldwide license to the foundational intellectual property covering CRISPR/Cas9 for all applications other than use as a human therapeutic. Under the terms of the license, Daiichi Sankyo is able to use CRISPR technology to support its R...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.